International Niemann–Pick Disease Alliance
12 December 2020
Orphazyme Statement to the NPC Community
Dear Global Community of NPC Patients, Families and Collaborators:
You may have seen the news announced on 10 December that Kim Stratton has decided to resign as CEO of Orphazyme following a dialogue initiated by the board of directors. Orphazyme will initiate a search for a new CEO immediately. Meanwhile, in order to ensure continuity going forward, Georges Gemayel, Chairman of the Board of Directors, will temporarily assist the executive team of Orphazyme with the day-to-day operations until a new CEO is appointed.
We want to assure you that this change in personnel does not affect our timelines as they have been communicated publicly or our confidence in our ability to bring arimoclomol to patients. We remain committed, as we have been for over 10 years, to bring arimoclomol forward to the NPC community. We look forward to continued work together to make this happen.
Should you have any questions, please don’t hesitate to reach out to Regan Sherman, Global Head of Patient Advocacy, firstname.lastname@example.org.